| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2972-2975.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
From the Departments of Cerebrovascular Disease (A.T., H.M., K.N., K.T., H.N.), Radiology and Nuclear Medicine (T.H., K.H.), and Clinical Physiology (K.M.), National Cardiovascular Center, Osaka, Japan; Department of Internal Medicine (T.M.), Hyogo College of Medicine, Hyogo, Japan; Deans Office (D.M.S.), Medical College of Georgia, Augusta, Ga; and Department of Hematology (T.S.), Osaka Minami National Hospital, Osaka, Japan.
Correspondence to Akihiko Taguchi, Department of Cerebrovascular Disease, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565 Japan. E-mail ataguchi{at}res.ncvc.go.jp
Received December 8, 2003; de novo received April 12, 2004; accepted May 11, 2004.
| Abstract |
|---|
|
|
|---|
Methods and Results The level of circulating immature cells, CD34-, CD133-, CD117-, and CD135-positive cells, in patients with a history of atherothrombotic cerebral ischemic events was analyzed to assess possible correlations with the degree of carotid atherosclerosis and number of cerebral infarctions. There was a strong inverse correlation between numbers of circulating CD34- and CD133-positive cells and cerebral infarction. In contrast, there was no correlation between the degree of atherosclerosis and populations of circulating immature cells. Analysis of patients with cerebral artery occlusion revealed a significant positive correlation between circulating CD34- and CD133-positive cells and regional blood flow in areas of chronic hypoperfusion.
Conclusions These results suggest a possible contribution of circulating CD34- and CD133-positive cells in maintenance of the cerebral circulation in settings of ischemic stress. Our data demonstrate the utility of a simple and precise method to quantify circulating CD34-positive cells, the latter providing a marker of cerebrovascular function.
Key Words: cerebral infarction cerebral ischemia antigens, CD34 stem cells
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
|
Atherosclerosis in the common and internal carotid arteries was analyzed by ultrasonography to determine plaque score as described previously.7 Cerebral infarcts (diameter >5 mm) were counted independently by a neurologist blinded to other parameters under study (number of circulating CD34+, etc) using T1-weighted, T2-weighted, and fluid-attenuated inversion-recovery MRI obtained with a 1.5-Tesla MRI scanner. The diagnosis of hypoperfusion was made angiographically. Regional cerebral blood flow (CBF), cerebral blood volume, oxygen extraction fraction (OEF), and cerebral metabolic rate of oxygen (CMRO2) were quantified by conventional steady-state 15O PET using a PET scanner (Shimadzu) as described.8 Cerebrovascular function was evaluated in patients with chronic hypoperfusion caused by major cerebral artery (carotid artery or M1 portion of the middle cerebral artery) occlusion or severe stenoses (>90%) without a major stroke. Twelve patients with 15 major arterial occlusions or stenoses had PET examinations.
To investigate the mobilization of immature cells after acute cerebral infarction, peripheral blood was quantified at 6 hours and 3, 7, 14, and 30 days after the onset of stroke. The episodes of acute cerebral infarction were confirmed by the diffusion image of brain MRI. Age-matched volunteers who had no history of cerebrovascular diseases and no neuronal deficiency were enrolled as controls (mean age, 67±4 years). Test-retest intraclass correlations were 0.88, 0.75, 0.86, and 0.86 for CD34, CD133, CD117, and CD135, respectively, obtained from 5 volunteers tested twice with an interval of at least 10 days between samples.
Univariant correlations were performed using Pearsons correlation coefficient and Spearmans correlation coefficient. Statistical comparisons among groups were determined using analysis of variance. Individual comparisons were performed using Students t test. In all experiments, mean±SE is reported.
| Results |
|---|
|
|
|---|
|
Several factors were found to influence the number of circulating CD34+ cells. Statistical analysis revealed a significant decrease in circulating CD34+ cells in patients with DM (0.5±0.1; non-DM, 1.2±0.1 cells/µL; P=0.01). In contrast, no change was observed in patients with hypertension (P=0.61), with hyperlipidemia (P=0.81), with smoking (P=0.64), or based on gender (P=0.36). In addition, treatment with HMG-CoA reductase inhibitors (P=0.81), compared with patients without hyperlipidemia, did not impact the number of CD34+ cells. In the control patient group, a decrease of circulating CD34+ cells was observed with aging (Figure 2B), although this was not observed in the patient group (Figure 2C). Comparing baseline levels of circulating CD34+ cells, there was a significant decrease in the patient group compared with age-matched controls (stroke, 1.1±0.1; control, 1.6±0.2 cells/µL; P=0.02).
We sought a possible correlation between circulating immature cells and the degree of arteriosclerosis of the common and internal carotid arteries in the patients with atherothrombotic cerebral ischemic events. However, there was no significant correlation between arteriosclerosis and circulating CD34+ (Figure 2D). This result was not surprising, because multiple risk factors and cell types contribute to progression of vascular lesions in major arteries. In contrast, because disruption of vascular homeostasis and repair are associated with cerebral infarction, we reasoned that a history of cerebral infarction might correlate with circulating immature cells. A strong correlation was observed between the number of infarcts and the absolute number of circulating CD34+ cells (Figure 2E) and CD133+ cells (Figure 2F). However, no significant correlation with regard to cerebral infarcts was observed with circulating CD117+ cells (Figure 2G) and CD135+ cells (Figure 2H).
In view of the critical role of endothelium in maintaining CBF, we evaluated cerebrovascular function in patients with chronic hypoperfusion. Direct correlations were observed between CBF (in the chronically hypoperfused area) and circulating CD34+ cells (Figure 2I) and CD133+ cells (Figure 2J). In addition, lower numbers of circulating CD34+ cells (Figure 2K) correlated with diminished CMRO2, although there was no significant increase in the OEF (Figure 2L). These observations suggest a contribution of CD34+ cells in homeostasis and repair of the cerebral circulation and maintenance of brain metabolism. No correlation was observed with the above parameters of vascular function and circulating CD117+ and CD135+ cells. Measurement of angiogenic growth factors in patient plasma, vascular endothelial growth factor, basic fibroblast growth factor, hemopoietic growth factor, and insulin-like growth factor-1 also demonstrated no correlation with indices of cerebrovascular function or the number of CD34+ cells (not shown).
| Discussion |
|---|
|
|
|---|
Patients with diabetes displayed a significant reduction in the number of circulating CD34+ cells. In view of the microvascular dysfunction that is characteristic of diabetes, this may not be surprising. Similarly, decreased circulating CD34+ cells with increasing age in healthy individuals may be associated with limited vascular renewal in older individuals. It was also of interest to note no change between levels of CD34+ cells in patients taking HMG-CoA reductase inhibitors. The latter results might reflect the positive effect of such drugs countering the negative effect of hyperlipidemia on circulating CD34+ cells. Such conclusions, of course, are at best tentative, because in this first report we have identified associations rather than proved a cause-effect relationship.
These observations suggest that diminished numbers of CD34+ and CD133+ cells impact maintenance and repair of cerebral vasculature. Precise measurement of circulating CD34+ cells provides a marker for cerebrovascular function in the setting of ischemic stress.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Taguchi A, Ohtani M, Soma T, et al. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. Eur J Vasc Endovasc Surg. 2003; 25: 276278.[CrossRef][Medline] [Order article via Infotrieve]
3. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360: 427435.[CrossRef][Medline] [Order article via Infotrieve]
4. Hamano K, Nishida M, Hirata K, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J. 2001; 65: 845847.[CrossRef][Medline] [Order article via Infotrieve]
5. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001; 97: 30753085.
6. Beck H, Voswinckel R, Wagner S, et al. Participation of bone marrowderived cells in long-term repair processes after experimental stroke. J Cereb Blood Flow Metab. 2003; 23: 709717.[Medline] [Order article via Infotrieve]
7. Sasaki T, Watanabe M, Nagai Y, et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke. 2002; 33: 14931496.
8. Hirano T, Minematsu K, Hasegawa Y, et al. Acetazolamide reactivity on 123I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: correlation with positron emission tomography parameters. J Cereb Blood Flow Metab. 1994; 14: 763770.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
G. Jickling, A. Salam, A. Mohammad, M. S. Hussain, J. Scozzafava, A. M. Nasser, T. Jeerakathil, A. Shuaib, and R. Camicioli Circulating Endothelial Progenitor Cells and Age-Related White Matter Changes Stroke, October 1, 2009; 40(10): 3191 - 3196. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P.W. Rouhl, R. J. van Oostenbrugge, J. Damoiseaux, J.-W. C. Tervaert, and J. Lodder Endothelial Progenitor Cell Research in Stroke: A Potential Shift in Pathophysiological and Therapeutical Concepts Stroke, July 1, 2008; 39(7): 2158 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Povsic and P. J. Goldschmidt-Clermont Review: Endothelial progenitor cells: markers of vascular reparative capacity Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 199 - 213. [Abstract] [PDF] |
||||
![]() |
K. Chu, K.-H. Jung, S.-T. Lee, H.-K. Park, D.-I. Sinn, J.-M. Kim, D.-H. Kim, J.-H. Kim, S.-J. Kim, E.-C. Song, et al. Circulating Endothelial Progenitor Cells as a New Marker of Endothelial Dysfunction or Repair in Acute Stroke * Supplemental Methods Stroke, May 1, 2008; 39(5): 1441 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Okada, H. Makino, A. Nagumo, T. Sugisawa, M. Fujimoto, I. Kishimoto, Y. Miyamoto, A. Kikuchi-Taura, T. Soma, A. Taguchi, et al. Circulating CD34-Positive Cell Number Is Associated With Brain Natriuretic Peptide Level in Type 2 Diabetic Patients Diabetes Care, January 1, 2008; 31(1): 157 - 158. [Full Text] [PDF] |
||||
![]() |
H.-K. Yip, L.-T. Chang, W.-N. Chang, C.-H. Lu, C.-W. Liou, M.-Y. Lan, J. S. Liu, A. A. Youssef, and H.-W. Chang Level and Value of Circulating Endothelial Progenitor Cells in Patients After Acute Ischemic Stroke Stroke, January 1, 2008; 39(1): 69 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. R. Santhanam, L. A. Smith, T. He, K. A. Nath, and Z. S. Katusic Endothelial Progenitor Cells Stimulate Cerebrovascular Production of Prostacyclin By Paracrine Activation of Cyclooxygenase-2 Circ. Res., May 11, 2007; 100(9): 1379 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Fadini, S. V. de Kreutzenberg, A. Coracina, I. Baesso, C. Agostini, A. Tiengo, and A. Avogaro Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk Eur. Heart J., September 2, 2006; 27(18): 2247 - 2255. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Bonsignore, P. Palange, U. Testa, A. Huertas, R. Antonucci, P. Serra, and G. Bonsignore Circulating CD34+ Cells Are Decreased in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, August 1, 2006; 3(6): 537 - 538. [Full Text] [PDF] |
||||
![]() |
H.C. de Boer, C. Verseyden, L.H. Ulfman, J.J. Zwaginga, I. Bot, E.A. Biessen, T.J. Rabelink, and A.J. van Zonneveld Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Werner and G. Nickenig Influence of Cardiovascular Risk Factors on Endothelial Progenitor Cells: Limitations for Therapy? Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 257 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, M. Britten, U. Kamper, S. Dimmeler, and A. M. Zeiher Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair Circulation, June 7, 2005; 111(22): 2981 - 2987. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Yamada, H Kubo, K Ishizawa, S Kobayashi, M Shinkawa, and H Sasaki Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair Thorax, May 1, 2005; 60(5): 410 - 413. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |